AMPK - a drug target in diabetes, cancer, and even neurodegenerative diseases – too good to be true?
Professor D. Grahame Hardie graduated in Biochemistry from Cambridge University in 1971, and became Professor of Cellular Signalling at the University of Dundee in 1994. He is a Fellow of the Royal Society, the Royal Society of Edinburgh, and the UK Academy of Medical Sciences. He was awarded the Rolf Luft prize for Endocrinology and Metabolism in 2008 and the Novartis Medal of the UK Biochemical Society in 2010. He has published over 350 scientific papers and given over 200 invited lectures. His major research achievement was to define the AMP-activated protein kinase (AMPK) stem, showing it to be a key player in obesity and Type 2 diabetes that is a target for the anti-diabetic drug metformin and the anti-inflammatory drug aspirin. He also discovered that the tumour suppressor LKB1 acted upstream of AMPK, which led to the current worldwide interest in the role of AMPK in cancer and cancer treatment.
Date: 22 March 2018, 10:00 (Thursday, 10th week, Hilary 2018)
Venue: NDM Building, Headington OX3 7FZ
Venue Details: Basement Seminar Room
Speaker: Professor Grahame Hardie (University of Dundee)
Organising department: Target Discovery Institute
Organiser: Dr John Davis (Alzheimer’s Research UK Oxford Drug Discovery Institute)
Organiser contact email address:
Part of: ARUK Oxford Drug Discovery Institute Seminar Series
Booking required?: Not required
Cost: FREE
Audience: Public
Editor: Keely Jones